An Assessment of the Impact of Pharmacogenomics on Health Disparities: A Systematic Literature Review

References

• Hosseinpoor AR , BergenN , KollerTet al. Equity-oriented monitoring in the context of universal health coverage . PLoS Med.11 , e1001727 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Whitehead M . The concepts and principles of equity and health . Health Promot. Int.6 , 217 – 228 ( 1991 ).
   Google Scholar
• EPEMED . Personalized Medicine in Europe – Enhancing Patient Access to Pharmaceutical Companion Products . European Personalized Medicine Association ( 2014 ). www.epemed.org/online/www/content2/104/107/910/pagecontent2/4339/791/ENG/EpemedWhitePaperNOV14.pdf .
   Google Scholar
• Shargel L , Wu-PongS , ABCY . Applied Biopharmaceutics and Pharmacokinetics, 5th ed.McGraw-Hill , NY, USA , 258 – 267 ( 2005 ).
   Google Scholar
• NIH . Precision Medicine Initiative Cohort Program ( 2016 ). www.nih.gov/precision-medicine-initiative-cohort-program .
   Google Scholar
• Sweeny K , GhaneA , LeggAM , HuynhHP , AndrewsSE . Predictors of genetic testing decisions: a systematic review and critique of the literature . J. Genet. Couns.23 , 263 – 288 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Welch VA , PetticrewM , O’NeillJet al. Health equity: evidence synthesis and knowledge translation methods . Syst. Rev.2 , 43 ( 2013 ).
   PubMedGoogle Scholar
• CRD . Systematic reviews: CRD’s guidance for undertaking reviews in healthcare . doi:10.1016/S1473-3099(10)70065-70067 . www.york.ac.uk/media/crd/Systematic_Reviews.pdf .
   Google Scholar
• Welch V , PetticrewM , TugwellPet al. PRISMA-Equity 2012 Extension: reporting guidelines for systematic reviews with a focus on health equity . PLoS Med.9 , 1 – 2 ( 2012 ).
   Web of Science ®Google Scholar
• PharmGKB . Drug Labels . 1 ( 2015 ). www.pharmgkb.org/view/drug-labels.do .
   Google Scholar
• Morrison A , PolisenaJ , HusereauDet al. The effect of English-language restriction on systematic review-based meta-analyses: a systematic review of empirical studies . Int. J. Technol. Assess. Healthcare28 , 138 – 144 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Guyatt G , OxmanAD , AklEAet al. GRADE guidelines: 1. introduction - GRADE evidence profiles and summary of findings . J. Clin. Epidemiol.64 , 383 – 394 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Kealey C , ChenZ , ChristieJet al. Warafin and cytochrome P450 2C9 genotype: possible ethic variation in warafin sensitivity . Pharmacogenomics8 , 217 – 225 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Limdi NA , ArnettDK , GoldsteinJAet al. Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European–Americans and African–Americans . Pharmacogenomics9 , 511 – 526 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Gladding P , StewartR , WebsterM , WhiteH . A simulation of warfarin maintenance dose requirement using a pharmacogenomic algorithm in an ethnically diverse cohort . Hear. Lung Circ.18 , S11 ( 2009 ).
   PubMedGoogle Scholar
• Chan SL , SuoC , ChiaKS , TeoYY . The population attribu fraction as a measure of the impact of warfarin pharmacogenetic testing . Pharmacogenomics13 , 1247 – 1256 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Panattoni L , BrownPM , AoB , Te WebsterM , GladdingP . The cost effectiveness of genetic testing for CYP2C19 variants to guide thienopyridine treatment in patients with acute coronary syndromes: a New Zealand evaluation . Pharmacoeconomics30 , 1067 – 1084 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Manrai AK et al. Genetic misdiagnoses and the potential for health disparities . N. Engl. J. Med.375 , 655 – 665 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Panattoni L , BrownPM , AoB , Te WebsterM , GladdingP . The cost effectiveness of genetic testing for CYP2C19 variants to guide thienopyridine treatment in patients with acute coronary syndromes: a New Zealand evaluation . Pharmacoeconomics30 , 1067 – 1084 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Plumpton CO , RobertsD , PirmohamedM , HughesDA . A systematic review of economic evaluations of pharmacogenetic testing for prevention of adverse drug reactions . Pharmacoeconomics34 ( 8 ), 771 – 793 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Anderson JL , GageBF , RosenbergYDet al. A pharmacogenetic versus a clinical algorithm for warfarin dosing . N. Engl. J. Med.369 , 2283 – 2293 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Kimmel SE , FrenchBF , KasnerSEet al. A pharmacogenetic versus a clinical algorithm for warfarin dosing . N. Engl. J. Med.369 , 2283 – 2293 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Finlayson AE , GodmanB , PatersonKet al. Personalizing healthcare: from genetics through payment to improving care? J. R. Soc. Med. 106 , 41 – 44 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Verhoef TI , RedekopWK , LangenskioldSet al. Cost–effectiveness of pharmacogenetic-guided dosing of warfarin in the United Kingdom and Sweden . Pharmacogenomics J.16 , 478 – 484 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Perera MA , CavallariLH , LimdiNAet al. Genetic variants associated with warfarin dose in African–American individuals: a genome-wide association study . Lancet382 , 790 – 796 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Kubo K , OharaM , TachikawaMet al. Population differences in S-warfarin pharmacokinetics among African–Americans, Asians and whites: their influence on pharmacogenetic dosing algorithms . Pharmacogenomics J. doi:10.1038/tpj.2016.57 ( 2016 ) ( Epub ahead of print ).
   Web of Science ®Google Scholar
• Daneshjou R , GamazonER , BurkleyBet al. Genetic variant in folate homeostasis is associated with lower warfarin dose in African–Americans . Blood124 , 2298 – 2306 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Simon T , VerstuyftC , Mary-KrauseMet al. Genetic determinants of response to clopidogrel and cardiovascular events . N. Engl. J. Med.360 , 363 – 375 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Scott SA , SangkuhlK , SteinCMet al. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update . Clin. Pharmacol. Ther.94 , 317 – 323 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Pereira NL , GeskeJB , MayrM , ShahSH , RihalCS . Pharmacogenetics of clopidogrel . Circ. Cardiovasc. Genet.9 , 185 – 188 ( 2016 ).
   PubMedGoogle Scholar
• Tan DSW , MokTSK , RebbeckTR . Cancer genomics: diversity and disparity across ethnicity and geography . J. Clin. Oncol.34 , 91 – 101 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• WHO . Closing the gap in a generation . Health Equity Through Action on the Social Determinants of Health . doi:10.1080/17441692.2010.514617 ( 2008 ). www.who.int/social_determinants/final_report/csdh_finalreport_2008.pdf .
   Google Scholar